Study links hormone signaling to canine mast cell tumor biology

Version 2

A newly published study in Animals examines whether reproductive status is tied to the molecular profile of canine cutaneous mast cell tumors in female dogs, an issue that has drawn growing attention as clinicians and researchers revisit the long-term biologic effects of gonadectomy. The investigators analyzed healthy skin and mast cell tumor samples from intact and gonadectomized females, focusing on genes involved in hormone signaling, proliferation, angiogenesis, and tumor behavior. Their central finding was that LHR expression was significantly increased in cutaneous mast cell tumors compared with healthy skin, reinforcing the idea that endocrine signaling may play a meaningful role in mast cell tumor biology. (pmc.ncbi.nlm.nih.gov)

That question didn’t emerge in a vacuum. Mast cell tumors are among the most common skin tumors in dogs, and prior literature has suggested that risk patterns may differ by sex, breed, body size, and reproductive history. The WSAVA reproduction guidelines note that, in female dogs, some studies have associated gonadectomy after 12 months with a higher incidence of mast cell tumors than earlier gonadectomy, while also emphasizing that pathogenesis is likely multifactorial and that more research is needed. Earlier work also showed that neoplastic mast cells in mast cell tumors express LHR, with higher expression reported in spayed and neutered dogs than in intact dogs. (onlinelibrary.wiley.com)

In the new study, the authors evaluated expression of VEGF, IGF-1, PCNA, Ki-67, c-KIT, LHR, FSHR, and ERα in skin samples from intact and gonadectomized female dogs, with and without cutaneous mast cell tumors. According to the paper summary, the work was designed to test whether gonadectomy-associated hormonal changes, including altered gonadotropin signaling, might influence expression of receptors and proliferative factors in tumor tissue. The most notable reported result was significantly higher LHR expression in mast cell tumors than in healthy skin, supporting the interpretation that LHR may be a biologically relevant component of these tumors rather than an incidental finding. (pmc.ncbi.nlm.nih.gov)

The broader research context also points toward a more complex tumor microenvironment in canine mast cell disease. A separate Frontiers in Veterinary Science study evaluated 117 surgically excised mast cell tumors from 73 dogs and found that higher intratumoral eosinophil infiltration, measured as the eosinophil-to-mast cell ratio, or EMR, was associated with high-grade tumors under both the Patnaik and Kiupel grading systems. That association held up in multivariable analysis, suggesting the local eosinophilic component of the microenvironment may add information beyond grade alone. The same study identified an exploratory EMR cutoff of 0.38 that showed good discrimination for low- versus high-grade Kiupel tumors on internal bootstrap validation, although the authors noted the threshold remains imprecisely estimated and needs external validation. Importantly, peripheral blood eosinophil counts were not significantly related to tumor grade, and most systemic inflammatory markers were not either, underscoring that local tumor biology may be more informative than circulating markers in this setting. (frontiersin.org)

Direct outside commentary on this specific paper appears limited so far, but the findings fit with a small, developing body of veterinary oncology and reproduction literature. Prior publications on LHR expression in canine mast cell tumors and reviews of gonadectomy-associated health effects have raised the possibility that persistent luteinizing hormone signaling after gonad removal could influence some cancers in susceptible tissues. That remains a hypothesis, not a clinical directive, and the current evidence does not establish that gonadectomy causes mast cell tumors or that hormone-receptor findings should alter standard-of-care management. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For practicing veterinarians, the immediate takeaway is not a change in how to diagnose or treat mast cell tumors, but a reminder that reproductive history may be worth documenting as part of the bigger clinical picture. If future studies link receptor or growth-factor expression to grade, recurrence risk, metastatic behavior, or treatment response, these markers could become more useful in prognostic stratification or research enrollment. The same applies to microenvironment features such as EMR, which may offer complementary histologic information if validated in larger cohorts. For now, histologic grading, staging, margin assessment, c-KIT-related evaluation, and case-specific treatment planning remain the backbone of care, while endocrine signaling and local inflammatory composition stay in the “important to watch” category. (pmc.ncbi.nlm.nih.gov; frontiersin.org)

The study also lands in a broader conversation with pet parents about spay timing and long-term health tradeoffs. The literature on gonadectomy and cancer risk in dogs is nuanced, often breed-specific, and not strong enough to support simple one-size-fits-all conclusions. This paper adds mechanistic texture to that discussion by suggesting a plausible biologic pathway, but it does not resolve the clinical question on its own. (onlinelibrary.wiley.com)

What to watch: The next important step is validation in larger cohorts with outcome data, especially studies that correlate hormone-receptor and growth-factor expression with tumor grade, recurrence, metastasis, survival, and any differences by timing of gonadectomy. It will also be worth watching whether local microenvironment measures such as EMR hold up across centers and prove clinically useful alongside existing grading systems. (pmc.ncbi.nlm.nih.gov; frontiersin.org)